301 related articles for article (PubMed ID: 19710593)
21. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.
Vingerhoets J; Tambuyzer L; Azijn H; Hoogstoel A; Nijs S; Peeters M; de Béthune MP; De Smedt G; Woodfall B; Picchio G
AIDS; 2010 Feb; 24(4):503-14. PubMed ID: 20051805
[TBL] [Abstract][Full Text] [Related]
22. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
[TBL] [Abstract][Full Text] [Related]
23. Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance.
Towner WJ; Cassetti I; Domingo P; Nijs S; Kakuda TN; Vingerhoets J; Woodfall B
Antivir Ther; 2010; 15(6):803-16. PubMed ID: 20834093
[TBL] [Abstract][Full Text] [Related]
24. Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionals.
Yeni P; Mills A; Peeters M; Vingerhoets J; Kakuda TN; De Smedt G; Woodfall B
Curr HIV Res; 2010 Oct; 8(7):564-76. PubMed ID: 20946097
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial.
Cohen CJ; Berger DS; Blick G; Grossman HA; Jayaweera DT; Shalit P; Thompson M; Peeters M; de Béthune MP; Voorspoels E; Mack R; Woodfall B
AIDS; 2009 Jan; 23(3):423-6. PubMed ID: 19114852
[TBL] [Abstract][Full Text] [Related]
26. Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.
Tudor-Williams G; Cahn P; Chokephaibulkit K; Fourie J; Karatzios C; Dincq S; Opsomer M; Kakuda TN; Nijs S; Tambuyzer L; Tomaka FL;
HIV Med; 2014 Oct; 15(9):513-24. PubMed ID: 24589294
[TBL] [Abstract][Full Text] [Related]
27. Etravirine.
Deeks ED; Keating GM
Drugs; 2008; 68(16):2357-72. PubMed ID: 18973398
[TBL] [Abstract][Full Text] [Related]
28. [Role of etravirine in combination antiretroviral therapy].
Domingo P
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
[TBL] [Abstract][Full Text] [Related]
29. The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients.
Hill AM; Cho M; Mrus JM
AIDS Rev; 2011; 13(1):41-8. PubMed ID: 21412388
[TBL] [Abstract][Full Text] [Related]
30. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
Imaz A; Llibre JM; Mora M; Mateo G; Camacho A; Blanco JR; Curran A; Santos JR; Caballero E; Bravo I; Gayá F; Domingo P; Rivero A; Falcó V; Clotet B; Ribera E
J Antimicrob Chemother; 2011 Feb; 66(2):358-62. PubMed ID: 21172789
[TBL] [Abstract][Full Text] [Related]
32. Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection.
Croxtall JD
Drugs; 2012 Apr; 72(6):847-69. PubMed ID: 22512366
[TBL] [Abstract][Full Text] [Related]
33. The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
Ruane PJ; Brinson C; Ramgopal M; Ryan R; Coate B; Cho M; Kakuda TN; Anderson D;
HIV Med; 2015 May; 16(5):288-96. PubMed ID: 25585528
[TBL] [Abstract][Full Text] [Related]
34. Etravirine for the treatment of HIV infection.
Seminari E; Castagna A; Lazzarin A
Expert Rev Anti Infect Ther; 2008 Aug; 6(4):427-33. PubMed ID: 18662109
[TBL] [Abstract][Full Text] [Related]
35. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
Fulco PP; McNicholl IR
Pharmacotherapy; 2009 Mar; 29(3):281-94. PubMed ID: 19249947
[TBL] [Abstract][Full Text] [Related]
36. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.
Johnson LB; Saravolatz LD
Clin Infect Dis; 2009 Apr; 48(8):1123-8. PubMed ID: 19275497
[TBL] [Abstract][Full Text] [Related]
37. Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?
Scott C; Grover D; Nelson M
AIDS; 2008 May; 22(8):989-90. PubMed ID: 18453859
[TBL] [Abstract][Full Text] [Related]
38. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
Arribas JR
Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
[TBL] [Abstract][Full Text] [Related]
39. Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.
Charpentier C; Roquebert B; Colin C; Taburet AM; Fagard C; Katlama C; Molina JM; Jacomet C; Brun-Vézinet F; Chêne G; Yazdanpanah Y; Descamps D;
AIDS; 2010 Nov; 24(17):2651-6. PubMed ID: 20802293
[TBL] [Abstract][Full Text] [Related]
40. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]